conduct of clinical trials, in obtaining the necessary approvals for additional clinical testing and for marketing of PI-88, market acceptance of the compound, general economic conditions, and other risks and uncertainties detailed from time to time in Progen's filings with the Australian Stock Exchange and the United States Securities and Exchange Commission.